Israel - Englisch - Ministry of Health

merck sharp & dohme israel ltd - aprepitant - capsules - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Israel - Englisch - Ministry of Health

merck sharp & dohme israel ltd - aprepitant - capsules - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Israel - Englisch - Ministry of Health

merck sharp & dohme israel ltd - aprepitant - capsules - aprepitant 125 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Israel - Englisch - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - posaconazole - suspension - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy. noxafil is also indicated for prophylaxis of invasive fungal infections in the following patients : - patients receiving remission- induction chemotherapy for acute myelogenous leukemia ( aml) or myelodysplastic syndromes ( mds ) expected to result in prologed neutropenia and who are at high risk of developing invasive fungal infections - hematopoietic stem cell transplant ( hsct) recipients who are undergoing high - dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. zygomycosis in patients intolerant of or with disease that is refractory to alternative therapy

Israel - Englisch - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - pneumococcal vaccine polyvalent - solution for injection - pneumococcal vaccine polyvalent 25 mcg / 0.5 ml - pneumococcus, purified polysaccharides antigen - pneumococcus, purified polysaccharides antigen - for vaccination against pneumococcal disease caused by those pneumococcal types included in the vaccine.

Israel - Englisch - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - hepatitis a virus antigen, inactivated - suspension for injection - hepatitis a virus antigen, inactivated 25 units / 0.5 ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in children and adolescents 12 months of age and older .

Israel - Englisch - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - hepatitis a virus antigen, inactivated - suspension for injection - hepatitis a virus antigen, inactivated 50 u/ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 2 years of age and older.

Israel - Englisch - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - asenapine as maleate - tablets sublingual - asenapine as maleate 5 mg - asenapine - asenapine - schizophrenia saphris is indicated for the treatment of schizophrenia in adults. the efficacy of saphris was established in two 6-week trials and one maintenance trial in adults bipolar disorder monotherapy: saphris is indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder. efficacy was established in two 3-week monotherapy trials in adults adjunctive therapy: saphris is indicated as adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar i disorder. efficacy was established in one 3-week adjunctive trial in adults.

Israel - Englisch - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - asenapine as maleate - tablets sublingual - asenapine as maleate 10 mg - asenapine - asenapine - schizophrenia saphris is indicated for the treatment of schizophrenia in adults. the efficacy of saphris was established in two 6-week trials and one maintenance trial in adults bipolar disorder monotherapy: saphris is indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder. efficacy was established in two 3-week monotherapy trials in adults adjunctive therapy: saphris is indicated as adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar i disorder. efficacy was established in one 3-week adjunctive trial in adults.

Israel - Englisch - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - rotavirus g1 reassortant; rotavirus g2 reassortant; rotavirus g3 reassortant; rotavirus g4 reassortant; rotavirus p1a[8] reassortant - oral solution - rotavirus p1a[8] reassortant 2.3 x10 ^6 iu/dose; rotavirus g2 reassortant 2.8 x10 ^6 iu/dose; rotavirus g4 reassortant 2.0 x10^ 6 iu/dose; rotavirus g3 reassortant 2.2 x10 ^6 iu/dose; rotavirus g1 reassortant 2.2 x10 ^6 iu/dose - rota virus diarrhea vaccines - rotateq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by types g1, g2, g3, g4, and g9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. the first dose of rotateq should be administered between 6 and 12 weeks of age